Research programme: phospholamban regulators - Edwards Lifesciences/Sangamo Therapeutics

Drug Profile

Research programme: phospholamban regulators - Edwards Lifesciences/Sangamo Therapeutics

Alternative Names: ZFP TF therapeutic angiogenesis programme - Sangamo; ZFP TFs for cardiovascular and vascular indications - Edwards Lifesciences/Sangamo

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Edwards Lifesciences Corporation; Sangamo BioSciences
  • Class Gene therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Heart failure

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 21 Mar 2007 Preclinical development is ongoing
  • 22 Nov 2005 Preclinical data from a media release have been added to the Heart failure pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top